REG - Immupharma PLC - Breakthrough Findings into Autoimmune Diseases

ImmuPharmaAnnouncement

09/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250109:nRSI7285Sa&default-theme=true

RNS Number : 7285S  Immupharma PLC  09 January 2025

 

 
09 January 2025

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Immupharma Announces Breakthrough Findings into Autoimmune Diseases

 

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development
company, announces innovative groundbreaking advancements in its preclinical
research program focused on P140 and the pathogenesis of autoimmune diseases.
This new discovery, conducted by the Company's R&D subsidiary ImmuPharma
Biotech, has yielded data that provides novel insights into autoimmune disease
mechanisms.

 

Importantly for our autoimmune therapy P140, especially for our lead
indication in SLE, these findings pave the way for:

 

·    Earlier and more accurate diagnostics

 

·    Identifying patients most likely to respond to P140 therapy

 

·    Improved monitoring of the patient's response to treatment with P140

 

Through this research, the company is making a significant step towards
personalised medicine in SLE and other autoimmune diseases.

 

The Company is not at this time releasing detailed data as these findings form
part of the ongoing expansion of our intellectual property portfolio including
additional patents for P140.

 

 

Commenting on this announcement, Tim McCarthy, CEO of ImmuPharma said: "We are
delighted to share these significant findings from ImmuPharma Biotech. This
breakthrough research confirms our confidence in P140, its future therapeutic
success and also creates potential new opportunities to strengthen our
intellectual property portfolio, positioning us at the forefront of innovation
in autoimmune disease therapies."

 

 

Commenting on this announcement, Sébastien Goudreau, CEO of ImmuPharma
Biotech said: "The findings we have announced today highlight the extremely
diligent and focused research we have been conducting behind the scenes at
Immupharma Biotech in order to better characterise and explain our lead asset
P140 and its application in autoimmune diseases, which is now gaining
significant attention within the biopharmaceutical industry."

 

 

 

Ends

This announcement contains inside information as stipulated under the UK
version of the Market Abuse Regulation no 596/2014 which is part of English
law by virtue of the European (withdrawal) Act 2018, as amended.  On
publication of this announcement via a regulatory information service, this
information is considered to be in the public domain.

 

 For further information please contact:

ImmuPharma PLC (www.immupharma.co.uk (http://www.immupharma.co.uk) )  +44 (0) 207 206 2650

 Tim McCarthy, Chief Executive Officer

 Lisa Baderoon, Head of Investor Relations                             + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                               +44 (0) 203 368 3550 (about:blank)

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                              +44 (0) 20 3650 3650

 Patrick Claridge, Bob Pountney

 SI Capital (Joint Broker)                                             +44 (0) 1483 413500

 Nick Emerson

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives. The lead program, P140, is a unique non-immunosuppressive
peptide for the treatment of SLE (Systemic Lupus Erythematosus) and CIDP
(Chronic Idiopathic Demyelinating Polyneuropathy) and preclinical models
suggest therapeutic activity for many other autoimmune diseases.

 

About Lupus (Systemic Lupus Erythematosus / SLE)

 

Lupus is a chronic inflammatory disease which is thought to affect some 16
million individuals worldwide. The current standard of care still consists of
steroid and anti-malarial therapies which have side-effects and poor response
in many patients. Recently more targeted monoclonal therapies are
GlaxoSmithKline's Benlysta and more recently, AstraZeneca's Saphnelo. There
still exists a high unmet medical need for a drug that has a strong efficacy
and safety profile.

 

 

 

For additional information about ImmuPharma please visit www.immupharma
(http://www.immupharma) .co.uk

 

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUKONRVSUARRR